BJH - volume 11, issue Abstract Book BHS, february 2020
L. Nevejan , D. Selleslag MD, S. Huygens , B. Cauwelier MD, PhD, J. Emmerechts MD, PhD, H. Devos MD
BJH - volume 11, issue Abstract Book BHS, february 2020
S. Servais MD, PhD, F. Baron MD, PhD, C. Lechanteur PhD, E. Baudoux MD, A. Briquet PhD, D. Selleslag MD, J. Maertens MD, PhD, X. Poiré MD, W. Schroyens MD, PhD, C. Graux MD, PhD, A. De Becker MD, R. Schots MD, PhD, P. Zachée MD, PhD, A. Ory , J. Herman , T. Kerre MD, PhD, Y. Beguin MD, PhD
BJH - volume 10, issue 6, october 2019
Y. Wouters PharmD, F. Nollet PhD, B. Cauwelier MD, PhD, J. Emmerechts MD, PhD, D. Selleslag MD, H. Devos MD
Patients lacking diagnostic criteria for myelodysplastic syndrome, but who show an unexplained persistent cytopaenia are classified as patients suffering from idiopathic cytopaenia of undetermined significance (ICUS). A fraction of these patients carry somatic mutations in genes which are also mutated in myeloid neoplasms. The significance of these mutations in ICUS patients is not well known and only few research papers have tried to correlate them with clinical outcome. ICUS patients carrying somatic mutations seem to have a higher progression rate to myeloid malignancies compared to unmutated patients. Some mutation profiles also show lower overall survival, similar to patients with (low-risk) myelodysplastic syndrome. Therefore, it seems useful to screen for somatic mutations in cytopaenic patients. The goal of this paper is to review recent literature regarding the significance of somatic mutations in cytopaenic patients and propose a screening protocol by evaluating a test protocol at the AZ Sint-Jan hospital Brugge-Oostende.
(BELG J HEMATOL 2019;10(6):231–40)
Read moreBJH - volume 10, issue 1, february 2019
D. Selleslag MD
The ASH 2018 conference in San Diego featured a number of exciting new studies with clinical relevance for the treatment of patients with acute myeloid leukemia (AML). The key studies that are discussed here are grouped in 3 broad treatment groups: targeted therapies, immunotherapy and allogeneic stem cell transplantation (allo SCT).
(BELG J HEMATOL 2019;10(1):36–40)
Read moreBJH - volume 9, issue 5, september 2018
A. Van de Velde MD, B. Willekens , L. Vanopdenbosch MD, O. Deryck , D. Selleslag MD, M. D’Haeseleer , A. De Becker MD, B. Dubois MD, PhD, D. Dierickx MD, PhD, G. Perrotta , V. De Wilde MD, PhD, V. Van Pesch MD, PhD, N. Straetmans MD, PhD, D. Dive MD, Y. Beguin MD, PhD, B. Van Wijmeersch MD, PhD, K. Theunissen , T. Kerre MD, PhD, G. Laureys MD, PhD
Multiple sclerosis is considered to be an immune mediated inflammatory disorder of the central nervous system. It mainly affects young, socioeconomic active patients. Although our armamentarium for this disease has significantly evolved in recent years some patients remain refractory to conventional therapies. In these cases, autologous haematopoietic stem cell transplantation can be considered as a therapeutic option. Decreasing morbidity, mortality and increasing patient awareness have led to rising inquiry by our patients about this treatment option. With the aim of a standardised protocol and data registration, a Belgian working party on stem cell therapy in multiple sclerosis was established. In this paper, we report the consensus protocol of this working party on autologous haematopoietic stem cell transplantation in multiple sclerosis.
(BELG J HEMATOL 2018;9(5):167–74)
Read moreBJH - volume 9, issue 3, june 2018
C. Lambert MD, B. Dubois MD, PhD, D. Dive MD, A. Lysandropoulos MD, D. Selleslag MD, L. Vanopdenbosch MD, V. Van Pesch MD, PhD, B. Van Wijmeersch MD, PhD, A. Janssens MD, PhD
Alemtuzumab (Lemtrada®) is a humanised monoclonal antibody indicated for the treatment of adult patients with relapsing/remitting multiple sclerosis with active disease defined by clinical or imaging features. Alemtuzumab demonstrated superior efficacy over active comparator in both treatment naive patients and those with inadequate response to prior therapy. Alemtuzumab is associated with a consistent and manageable safety and tolerability profile. Treatment with alemtuzumab for multiple sclerosis increases the risk for autoimmune adverse events including immune thrombocytopenia. Complete blood counts with differential should be obtained prior to initiation of treatment and at monthly intervals thereafter for 48 months after the last infusion. After this period of time, testing should be performed based on clinical findings suggestive of immune thrombocytopenia. If immune thrombocytopenia onset is confirmed, appropriate medical intervention should be promptly initiated, including immediate referral to a specialist. This paper presents the consensus of Belgian multiple sclerosis specialists and haematologists to guide the treating physician with practical recommendations.
(BELG J HEMATOL 2018;9(3):118–23)
Read moreBJH - 2018, issue Abstract Book BHS, february 2018
L. Naesens , D. Selleslag MD, F. Nollet PhD, H. Devos MD
Top
